AACR Meeting Presentations Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI): new translational data from the Phase 1b trial of CMP-001 in subjects with advanced melanoma (Sunday) Blueprint Medicines Corporation (NASDAQ: BPMC): interim analysis of Phase 2 data for avapritinib in patients with advanced systemic mastocytosis (Sunday) Mirati Therapeutics, Inc. (NASDAQ: MRTX) and BeiGene, Ltd. (NASDAQ: BGNE): Phase 1b safety/tolerability and preliminary antitumor activity data for Mirati's sitravatinib plus BeiGene's tislelizumab in patients with advanced platinum-resistant ovarian cancer as well as patients with PD-(L)1 refractory/resistant unresectable or metastatic melanoma (Sunday) Beigene: results from the Phase 3 study of tislelizumab versus docetaxel as second or third-line therapy for patients with locally advanced or metastatic non-small cell lung cancer (Monday)